Cancer
Conditions
Brief summary
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
Detailed description
Primary Objectives: To assess the efficacy of ustekinumab for clinical remission/response of immune-related diarrhea and/or colitis To assess the efficacy of ustekinumab in reducing fecal calprotectin levels Secondary Objectives: To assess steroid free IMDC remission by week 4 and 8 To assess the IMDC recurrence by week 4 and 8 To assess the time duration to IMDC recurrence and overall survival To assess the efficacy of ustekinumab to achieve endoscopic remission of immune-related diarrhea and/or colitis To identify immune signatures related to GI irAEs and those specific to responsiveness to ustekinumab To identify pro-inflammatory immune signatures in serum To assess patient symptom and QOL
Interventions
DRUGUstekinumab
Given by infusion
Sponsors
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients who receive any type of ICI therapy 2. Patients with ≥ grade 2 immune-related diarrhea and/or colitis according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 within 45 days prior to enrollment in study 3. Patients with ability to understand and willingness to sign informed consent 4. Patients with a diagnosis of any type of solid tumors on ICI systemic therapy 5. No concern for active concomitant GI infection for immune-related diarrhea and/or colitis work up at the time of protocol therapy initiation as confirmed by stool tests or as per the treating physician based on clinical presentation 6. Patient who has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g. lifelong positive T- spot due to BCG inoculation, chronic colonization) prior to initiation of diarrhea/colitis treatment and/ or imaging (e.g. CXR, CT CAP etc) confirms the absence of active infections (e.g. TB) within 60 days prior to initiation of protocol therapy 7. Concurrent or prior cancer therapy (non-checkpoint inhibitors) that are not deemed as a significant contributor of the GI adverse event can be allowed in the study. 8. Patients can be on the steroid treatment within 45 days before Ustekinumab 9. Patients with non- GI immune-related adverse events (irAEs) can be enrolled if there is no contraindication to the use of ustekinumab in the treatment of the non-GI irAEs present 10. Patients with a new index event of . grade 2 immune-related diarrhea and/or colitis may be enrolled if previous IMDC event was . 1 year ago with successful treatment and clinical remission
Exclusion criteria
1. Patients younger than 18 years of age 2. Patients with persistent gastrointestinal infection confirmed with positive testing despite completing 5 days of antibiotics 3. Patients with history of inflammatory bowel disease and/or radiation enterocolitis with active disease status at the time of study treatment initiation 4. Pregnant and breastfeeding women 5. Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \> 1 year prior to consent and/ or clear documentation states that patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to enrollment in study 6. Patients who develop concurrent non-GI toxicity (irAEs) at the time of study treatment initiation, with contraindication to the use of ustekinumab in the treatment of the non GI irAEs present 7. Patients have already received other biologic treatment for IMDC such as infliximab, vedolizumab, EXCEPT if these drugs were used in a previous IMDC event that occurred ≥ 1 year earlier at which time there was complete resolution of the disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Adverse Events | Through study completion; an average of 1 year | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Countries
United States
Contacts
CONTACTYinghong Wang, MD,PHD
PRINCIPAL_INVESTIGATORYinghong Wang, MD,PHD
M.D. Anderson Cancer Center
Outcome results
None listed